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Abstract 
High-throughput screening and rational design can be used to create bioactive compounds with 
high affinity for selected therapeutic targets. However, a significant challenge in preclinical drug 
development is the identification of off-target proteins that contribute to phenotypic effects. This limits 
the understanding of the molecular basis of such effects, thus subverting rational drug design and 
hindering the identification of new therapeutic targets. Most previous strategies for proteome-wide target 
identification (target ID) have involved incubating cell lysates with compound-conjugated affinity resins. 
Despite their simplicity, such approaches can subject the proteome to conditions that prevent the detection 
of small molecule-protein interactions.  The yeast three-hybrid system is an attractive alternative that uses 
genetic tools to screen for protein-small molecule interactions in cellulo. This thesis describes efforts to 
improve the utility of the yeast three-hybrid system to screen for drug targets.  The proposed 
improvements utilize 1) the native fluorescence of green fluorescent protein (GFP) to identify interactions 
by flow-cytometry and fluorescence-activated cell sorting (FACS) and 2) the extreme affinity of 
streptavidin to search the mammalian proteome with biotinylated probes. The first objective required 
improvements to the sensitivity and dynamic range of a reporter vector encoding a popular GFP spectral 
variant. A new reporter vector was constructed and shown to exhibit better fluorescent properties 
compared to an existing reporter in a yeast one-hybrid assay. This reporter was also used to detect ligand 
dependent dimerization of the estrogen receptor β and progesterone receptor proteins. The second goal 
involved efforts to create a reduced valency streptavidin to enhance sensitivity for detection of 
biotinylated molecules in yeast three-hybrid systems. Circular permutations of wild-type and a low 
affinity mutant of streptavidin were constructed and fused to create dimeric streptavidins with variable 
valency. These constructs were tested with yeast three-hybrid assays using a GFP variant reporter, and 
shown to have altered profiles in fluorescence-based assays. 
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CHAPTER 1.  Strategies for Identification of Protein Targets of Small Molecules 
Introduction 
Modern drug discovery programs are largely target oriented. Biomolecules (usually proteins) 
shown to be influential, if not essential, in disease progression are carefully chosen and attacked with a 
choice of iterative strategies aimed at safely modifying function (usually inhibition) and stifle the 
resulting ailment or resulting symptoms.  Although direct, these strategies often underestimate the 
promiscuous nature of many small molecules. Consequently, toxic off-target effects may be missed until 
much later in the drug development process. These efforts are totally dependent on the “druggablilty”
1
 
and disease relevance of the chosen target, and likewise are almost totally wasted if target validation is 
errant or incomplete. These factors perhaps explain why the optimistic adoption of target-based drug 
discovery, largely replacing physiology-based methods in the 90s, has coincided with a decline in 
productivity in the pharmaceutical industry.
2
 This assessment has led many to readopt more systematic 
approaches that probe biological outcomes in early drug discovery with phenotypic screens of cellular or 
whole organismic model systems.
3, 4
 Yet even with a return to holism in early drug discovery, there is still 
much to be gained from a mechanistic understanding of phenotypic outcomes, particularly target 
identification.
5
 A well understood target is still the basis for rational drug design, which can greatly 
enhance optimization of phenotypically chosen compounds with structure activity relationship (SAR) 
studies and structure-based drug design. Target ID efforts could also lead to the discovery of new target-
based drug discovery strategies. 
Affinity Chromatography of Cell Lysates 
The classical method used to discover targets of bioactive small molecules is to attach an 
immobilizing functional group so that the molecule can “catch” binding proteins from a mixed suspension 
of possible targets, usually a cell lysate or protein extract.
5, 6
 The immobilization tag allows non-
interacting proteins to be „washed‟ away using an aqueous buffer and discarded, thus enriching binding 
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partners that are subsequently purified using protein-denaturing conditions or excess unmodified drug. In 
drug affinity chromatography, the drug is effectively transformed into a target purification tool. 
Separation of interacting proteins is achieved by SDS-PAGE, as depicted in Figure 1.1A. Identification of 
gel-extracted protein bands utilizes mass-spectroscopy based protein sequencing and/or 
immunoprecipitation.       
As the oldest and still most prolific method for target ID, affinity chromatography has undergone 
much iteration.
7, 8
 The simplest version directly links the compound of interest to a solid support matrix 
(e.g. agarose beads) to perform affinity chromatography. Many vendors (e.g. Biorad, Pierce, Sigma) sell 
these supports, or resins, chemically activated (e.g. with NHS esters) to bond covalently with a particular 
functional group (e.g. amine), which can be added to the drug by the user if necessary. The drug is usually 
tethered to the resin with a long, hydrophilic linker to minimize influence the resin might have on binding 
properties of the drug. Even so, many investigators have instead chosen to tag compounds with biotin 
(aka biotinylation) and incubate the derivative with cell lysate. In these experiments the protein 
streptavidin is immobilized to the support matrix, and can be added to the cell lysate before or after probe 
binding. The biotin tag binds streptavidin with virtually irreversible affinity (Kd ≈10
-14
 M), providing a 
noncovalent platform for target enrichment. If the tagged small molecule is suitably cell permeable, the 
biotinylated compound can be incubated with live cells and then lysed for chromatography. This allows 
for ligand-protein interactions to occur in their native cellular environment. Biotinylation also allows the 
modified probe to be tested to ensure the tag does not disrupt biological activity and target affinity.  
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Figure 1.1. Schematic representation of affinity chromatography outcomes in which the drug is tethered 
to a solid support resin, usually directly or through a biotin tag (which binds to a streptavidin fused 
matrix). Proteins still attached to the drug after washing are eluted and investigated by SDS-PAGE (A-D) 
or mass spectroscopy (E). In a typical affinity assay (A), many non-specific interacting proteins or 
partners are eluted with the target. To identify these false positives, a separate chromatography assay is 
carried out with a biologically inactive analogue of the drug (B), excess untagged drug (C), or a second 
batch of the affinity probe with washed extract (D). Alternatively, cell lysates of the original and control 
assay are composed of heavy (H) and light (L) isotopically labeled proteins (D), respectively. The elutants 
from these assays are pooled, digested with trypsin, and then compared using mass spectroscopy. 
 
In the typical chromatography experiment, many proteins bind to the matrix through nonspecific 
interactions that are maintained throughout the washing step. Eluting with excess untagged compound 
may help reduce nonspecific binding proteins from eluting with the target(s), especially those that interact 
with the support matrix itself. In addition, several control experiments have been reported to distinguish 
genuine targets from nonspecific binding proteins. These controls use subtle variations of the standard 
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protocol, in which they run in parallel. The SDS-PAGE gels of the eluted proteins from the control and 
original assay are compared to find protein bands that warrant identification. A so called comparison 
control uses a probe that is a biologically inactive analogue of the drug in question. The chromatography 
protocol is otherwise identical, and therefore the same set of proteins should be eluted (Figure 1.1B), 
except target protein(s) whose affinity is disrupted by the modification. In a competition control, depicted 
in Figure 1.1C, excess untagged drug is incubated with the cell lysate along with the probe. These 
conditions favor target binding to the free drug over the affinity probe, and therefore impede binding to 
the resin. Target proteins bound to the untagged drug are washed with other free proteins. The absence or 
lower intensity of resulting PAGE bands, compared to the outcome of original assay, indicates the 
interaction is specific. Another variation, the serial control, incubates the washed cell lysate of the original 
assay with a second batch of affinity matrix (Figure 1.1D). Specifically bound proteins are expected to 
yield more prominent bands in the PAGE gel of the first batch, whereas nonspecific binding proteins 
should produce roughly equivalent intensity bands.  
A recently reported affinity chromatography method uses a competition control with stable 
isotope protein labeling with amino acids in culture (SILAC) to streamline analysis of eluted protein.
9
 
Two separate cultures are grown, one under normal conditions and the other in media containing heavy 
isotopically labeled arginines that are incorporated into cellular proteins. Each cell culture is lysed and 
incubated with drug-conjugated matrix, with the competition control applied to the natural isotope lysate 
(Figure 1.1E, this is expected to reduce target protein binding to the matrix). After incubation, the lysates 
are pooled, washed, eluted, and proteolytically digested for MS analysis of peptide fragments. 
Homologous fragments from the original and control assays can be readily differentiated and quantified. 
Target proteins are expected to yield high heavy-to-light fragment ratios (H/L), due to the competitive 
displacement of these proteins in the natural isotope lysate. It seems feasible that SILAC could also be 
applied to a comparison control (using an inactive analogue as described previously). 
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Table 1.1. Selected example of affinity chromatography assays for proof-of-principle or target discovery. 
 
 
A significant criticism of affinity chromatography is that it places a high value on equilibrium 
binding kinetics, which is not always indicative of biological activity. These experiments make the 
implicit assumptions that drugs bind their targets with significantly higher affinity then the remaining 
proteome, and that targets have ample cellular concentrations for detection. However, many drug targets 
have low cellular concentrations and bind their drug ligand with moderate affinity.
10
 These properties put 
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affinity chromatography at a disadvantage for discovering such targets. Low protein concentration may be 
compensated for by maximizing the total lysate used in a given assay. To address affinity, photoreactive 
groups have been attached to drug affinity probes to facilitate cross-linking to target proteins.
11, 12
 
Affinity Assays of Expressed cDNA Libraries 
A more assertive strategy to overcome poor drug-target kinetics is to clone the genes of proteins 
to be screened into recombinant systems where expression can be tightly controlled. Expression-cloning 
target discovery methods offer the additional benefit of maintaining a traceable link between gene and 
gene product, allowing for selective amplification of potential target genes and identification with DNA 
sequencing. Also, with overexpression it is generally faster and cheaper to prepare large amounts of 
protein necessary for binding assays. These advantages come at the cost of expressing screened proteins 
in a foreign environment and/or at exogenous concentrations, resulting in the loss of native protein 
characteristics that may be important for probe affinity. For example, post-translational modifications of 
proteins in the mammalian cell are often essential for molecular recognition, but these modifications may 
not be mimicked with heterologous or in vitro expression. These strategies usually fuse participating 
proteins to a common protein or protein domain necessary for the assay, which can also alter binding. 
 Phage display is a platform that expresses cloned mammalian proteins on the head of a virus to 
present them to the probe.
13,14
 Mammalian genes are cloned into separate phage genomes, each fused to 
the gene of a phage coat protein.  The expressed protein localizes to the exterior of the viral coat, where it 
can interact with an immobilized affinity probe. After binding and washing, eluted proteins remain fused 
to host bacteriophages that encode the supposed target‟s gene. Bacteria are infected with these phages for 
amplification of genes, which may be expressed for iterative chromatography runs (Figure 1.2). Targets 
may be identified directly from protein (as described earlier) or by sequencing the gene embedded in the 
phage genome. 
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Figure 1.2. Schematic representation of a phage display assay of a cloned protein library. Proteins are 
fused to a phage coat protein and assayed with affinity chromatography. Eluted proteins can be amplified 
by infection of bacteria. Proteins can be identified with SDS-PAGE/MS or through sequencing of host 
phage DNA (colored DNA fragments).  
  
In mRNA display, an in vitro alternative to phage display, screened proteins are fused almost 
directly to the genes that encode them. A cDNA library is first transcribed in vitro to produce a mixed 
mRNA population, followed by ligation of a puromycin-DNA cassette to the 3‟ end of each transcript.
15,16
 
The mRNA is fully translated in vitro, but the cassette prevents translational termination and triggers the 
formation of a C-terminal amide bond with the puromycin amine. The mRNA-protein fusion is purified, 
reverse transcribed, and incubated with the affinity probe. Following washing, eluted cDNA serves as a 
template for polymerase chain reaction (PCR) amplification (Figure 1.3). The amplified double-stranded 
cDNA can be transcribed to mRNA for additional rounds of screening. Like phage display, enriched 
proteins can be identified either directly or via their genetic precursors. To my knowledge, this method 
has only been reported in proof-of-concept studies. 
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Figure 1.3. Schematic representation of an mRNA display assay, in which cDNA/mRNA-protein 
constructs are screened with affinity chromatography. Eluted constructs may be identified by sequencing 
of cDNA or amplified by PCR and transcription, creating an enriched mRNA pool for repeating the 
procedure. Proteins can be identified directly with SDS-PAGE/MS.  
 
In most target ID strategies, including those already discussed, the immobilized drug serves as the 
anchor for affinity-based target enrichment. In contrast, several assays immobilize expressed proteins and 
use a tagged drug to report the interaction. For example, drug-westerns immobilize expressed proteins, 
from localized E. coli colonies, onto nitrocellulose paper that is incubated with the affinity probe.
17
  
Unbound probe is washed away, and a localized signal (e.g. chemiluminescence, fluorescence) is 
produced by the tag. The location of the signal can then be traced back to the E. coli expression host for 
amplification and identification. In a similar manner, microarray technologies, traditionally used for DNA 
hybridization assays, have also been employed for target ID.
18,19
 Each expressed fusion protein is 
immobilized, or spotted, to a small section of a functionalized surface (e.g. microscope slide) using a 
protein tag (e.g. GST), as depicted in Figure 1.4. The surface is then incubated with the labeled drug, 
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washed and assayed. The bound probe leaves a binding profile of the drug for the entire library, which 
can easily be compared to other compounds using the same array and assay conditions. Unfortunately, 
this technique requires time intensive purification of individual participating proteins. The concentrated 
immobilization of proteins in these assays may lead to greater interference with probe binding than with 
other expression-based strategies. 
 
 
Figure 1.4. Schematic representing a protein microarray outcome in which screened protein library is 
spotted individually on a derivitized surface. After binding, unbound drug is washed from the array. The 
drug is labeled to be able to give a localized signal for identifying its binding partner(s).   
 
A variation on the microarray platform indirectly spots the protein library by expressing 
individual proteins in localized, adherent mammalian cell populations.
20
 These living microarrays are 
created by spotting the corresponding cDNA to the array, then overlaying the slide with transfection 
reagent, and finally incubating the slide in detached cell culture which naturally adhere themselves to the 
surface. Prepared slides can then be incubated with the cell permeable probe, washed, and analyzed to 
obtain an in cellulo protein binding profile for the compound. However, inconsistent transfection and 
protein expression hinder assay reproducibility and therefore drug profile comparisons. 
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Tag-free Target ID Strategies 
  Drug labeling is a necessary evil for all target ID methods discussed thus far, and no universal 
tagging strategy exists. Discovering modifications that do not alter drug pharmacology can be a 
bottleneck requiring significant time and expertise. Most “tagless” strategies employ functional assays 
that are more abstract and require confirmation with more concrete binding studies.  
Recently a novel binding assay was reported that recognizes that higher levels of protein structure 
are stabilized in a ligand-bound state.
21,22
 Drug Affinity Response Target Stability (DARTS)
23
 aims to 
take advantage of the resistance to proteolysis
24
 afforded by this stabilization. This simple assay 
comprises of equivalent protease treatment of cell lysates treated with varying concentrations of drug. 
Bound proteins are negatively selected by proteolysis, and are identified by variable band intensity on an 
SDS-PAGE gel. Higher concentrations of drug theoretically enhance resistance to proteolysis in drug 
targets by shifting the kinetics to a stabilized, ligand-bound state. The assay has been used to confirm 
several drug targets from cell lysates,
25
 including EF-1α for didemnin B. Detection sensitivity is a concern 
because resistant proteins can‟t be amplified, but DARTS is unique in its claim to identify drug targets 
with a binding assay that does not require modification of the drug or proteins being screened. 
Biochemical suppression is a functional but tagless method that attempts to identify drug targets 
through iterative protein fractionation. This strategy requires that the drug induces notable inhibition of 
activity in an in vitro assay (e.g. actin assembly) of a protein extract. Fractions of untreated extract are 
added to aliquots of unfractionated extract that has been drug inhibited,
26
 as depicted in Figure 1.5. 
Fractions containing target proteins are expected to „treat‟ inhibition, restoring assay activity at least in 
part. Theoretically this is a consequence of an increase in drug binding sites from these fractions, shifting 
kinetics towards an increase in unbound target. From here iterative fractionation of the suppressing 
fractions can be carried out until the target(s) is isolated and identified.  Unfortunately, suppressing 
fractions may instead (or additionally) contain protein(s) which functionally complement the target‟s 
11 
 
inhibition (e.g. a downstream component of the target‟s biochemical pathway), thereby confounding 
interpretation of results. 
 
Figure 1.5. Schematic depicting a biochemical suppression strategy that uses an in vitro activity assay. 
For simplicity, only unbound target produces activity. Aliquots of the drug inhibited sample (upper right) 
are „treated‟ with fractions of the untreated sample (upper left). Only fractions with drug target should 
restore assay activity (center). Iterative fractionation (not shown) and assays are used to enrich the target 
for identification.  
 
Yeast Genetic Systems 
The model eukaryote Saccharomyces cerevisiae,  has been used to discover drug targets.
27
 Yeast 
have proven themselves invaluable tools for understanding mammalian cellular processes and diseases,
28
 
in part because they are much cheaper, faster, and easier to maintain than many other model organisms or 
mammalian cell lines. Genetic manipulation of yeast, both chromosomally and through the introduction 
of exogenous plasmids, has proved to be much easier in yeast then higher organisms. Their utility has 
been enhanced with the sequencing of the entire genome in 1996. Since then, mutant strain collections 
have been produced in which each of the nearly 6,000 genes have been individually deleted,
29
 many of 
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which have known human homologs. Even before this, yeast have been used to discover the molecular 
targets of drugs such as rapamycin,
30
 using targeted yeast mutations.  
Target discovery using yeast can take advantage of modern computational tools that enable 
cataloguing, comparing and deconvoluting large biological data sets. These strategies operate on a model 
where the drug inhibits its target in manner that mimics the reduction or complete absence of that protein 
from the cell. One such strategy monitors the competitive growth of pairs of drug treated diploid yeast 
strains. One assayed strain possesses a single functional copy of a screened essential gene.
31,32
 The 
decrease in gene copy number theoretically reduces the resulting protein‟s concentration. If this protein is 
a drug target, the protein concentration differential may confer a drug induced competitive growth 
disadvantage (possible lethality) to the single copy strain, as depicted in Figure 1.6. This phenotypic 
difference should be dose dependent, requiring a certain concentration to sufficiently inhibit the target 
concentration in the single copy strain, but that is insufficient to inhibit the increased target concentration 
in the wild-type strain. Confirmation of the phenotypic influence of that protein can be achieved by 
overexpression,
33
 which should reverse the effect and perhaps result in a competitive advantage. Like 
other functional strategies, it is tenuous to conclude from these assays whether an indicated gene product 
is the target of the drug assayed, or a protein bearing some functional relationship with the target. Because 
not all gene copy reductions confer this type of protein reduction, other methods to reduce protein 
concentrations have been devised (e.g. protein destabilization, siRNA).
34
 Inherently this method can only 
apply to drugs able to impact yeast growth. 
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Figure 1.6. Schematic representation of a drug-induced haploinsufficiency competition assay of an 
essential target gene. In this example, diploid yeast with two copies of the target gene (green) produces 
twice as much target protein as the strain possessing only one gene (orange). Untreated yeast strains grow 
at equal rates. Drug treatment fully inhibits the product of one gene copy, stifling growth in the mutant 
single copy strain. Inhibition of the wild-type strain is reduced due to increased target protein content, and 
therefore growth is relatively unaffected.    
 
Another strategy compares gene expression profiles of drug treated wild-type haploid yeast to 
profiles of untreated gene knockout (KO) strains.
35
 Since many drugs act by functionally “knocking out” 
their target(s), mRNA levels (quantified with cDNA microarrays) of functionally associated proteins may 
reflect this.   In theory, targets of new compounds could be identified by profiling mRNA expression of 
drug treated yeast and comparing results to catalogued profiles of KO strains.  
This manner of pattern matching is not limited to mRNA expression. A blunter example that has 
been reported is the comparison of drug induced synthetic lethality with genetic synthetic lethality.
36
 For 
this strategy, a collection of nonessential gene deletion strains is first arrayed. To create a synthetic lethal 
profile, a common second nonessential gene is knocked out in all strains, and the effect on cell viability is 
catalogued. If the products of the two nonessential genes interact or participate in a common pathway, a 
double knockout (DKO) is more likely to induce lethality.
37
 This understanding has been used in yeast 
and other model organisms to study protein-protein interactions. Similarly, if a drug functionally knocks 
out the product of a nonessential gene, it should reduce viability in KO strains where a functionally 
associated protein is absent. The drug induced lethality on each KO strain is catalogued and compared to 
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the viability of DKO strains. Theoretically, the genetic and drug-induced lethality profile of a target gene 
should bear strong similarity, as depicted in Figure 1.7. 
 
 
Figure 1.7. Schematic depicting a small synthetic lethality profile of 6 possible target proteins (1-6) and 
drug treatment (right), based on three random nonessential genes (A, B, C). Each square in the main grid 
catalogues the viability of the DKO strain of intersecting genes (e.g. A and 1), and on the right viability of 
drug treated KO strain (A, B, C). An X indicates the strain did not grow in rich media. Target gene 
deletion (2) and drug treatment both induce lethality in A and C KO stains (as does gene 1).  
 
As previously discussed, these functional assays are rarely sufficient to identify a physical drug-
target interaction with the confidence of binding assays. However, yeast affinity-based reporter systems 
have been developed for detecting molecular interactions in cellulo. These systems were first employed 
for the detection of protein-protein interactions,
38
 in what is known as the yeast two-hybrid system.  
The yeast two-hybrid system essentially works by coupling yeast transcriptional machinery to the 
interaction in question. Specifically, a pair of interacting proteins is required to initiate the expression of a 
tailored reporter gene. In a simple transcription model (Figure 1.8A), a monomeric transcription factor 
contains two domains, a DNA binding domain (DBD) and an activation domain (AD). The DBD has 
sequence specific DNA affinity which localizes the transcription factor to the gene or genes to be 
activated, while the AD recruits the transcriptional machinery which ultimately initiates proper RNA 
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polymerase function.  In a yeast two-hybrid system (Figure 1.8B), the DBD and AD are fused to two 
different mammalian proteins, creating two hybrid proteins. Proper function of the transcription factor can 
only be restored with suitable affinity between these hybridized mammalian proteins. For the purpose of 
the assay, the mammalian protein fused to the DBD is called the bait (DBD-bait), and the AD is fused to 
the prey (AD-prey). The recognition sequence of the DBD employed is manipulated to localize the 
system and express the desired reporter gene. In the first yeast two-hybrid systems, fragments of the yeast 
gene GAL4 were cloned to make the DBD and AD. The Gal4p is a transcription factor of the yeast 
galactose metabolism pathway, initiating over 1,000 fold expression of both GAL1 and GAL10.
39
 
Therefore, cloning the promoters for either GAL1 or GAL10 upstream of a suitable gene creates a 
dynamic reporter for the interaction in question. The galactose pathway is still the biological basis for 
most yeast hybrid systems, including the conditional expression of proteins DBD-bait, AD-prey in many 
experiments. However, the Gal4 DBD and AD have for many investigators been replaced by DBDs and 
ADs from other organisms, commonly the LexA DBD and B42 AD from E. coli.
40
 A LexA-based yeast 
two-hybrid system is sometimes referred to as a yeast interaction trap. These changes were made in part 
to prevent the system from disturbing normal cellular function due to overexpression of GAL4 domains.
41
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Figure 1.8. Schematic depiction of yeast one- (A), two- (B), and three- (C) hybrid systems. Reporter 
expression is activiated by localizing the activation domain (AD) to the promoter of the reporter gene 
(green arrow). The DNA binding domain (DBD) localizes the system to the promoter, which is directly 
fused to the AD in the one-hybrid system. The two-hybrid system depends on bait and prey dimerization 
for reporter activation, which is mediated by a small-molecule (CID) in the three-hybrid system. D)  
Schematic of yeast colonies in three-hybrid screen in which each colony possesses identical CID and bait 
protein. Each colony expresses a different prey, which must bind the drug (tethored to the anchor moeity, 
AM) to activate reporter expression.  
 
A derivative of this assay used to study protein-small molecule interactions, termed the yeast 
three-hybrid system,
42
 requires only the addition of a small-molecule to mediate bait and prey 
„dimerization‟. This compound is thus termed a chemical inducer of dimerization (CID). The CID serves 
as a third hybrid: a chimera of two moieties, one with affinity to the bait and the other with affinity to the 
prey (Figure 1.8C). For target screening (Figure 1.8D), this hybrid consists of the drug tagged by an 
established high affinity ligand for the bait or prey (by convention usually the bait). This high affinity 
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interaction creates a platform, or anchor moiety, for screening cloned proteins against the tethered query 
compound. An example of a validated anchor moiety is the protein-ligand duo dihydrofolate reductase 
and methotrexate (DHFR-Mtx),
43
 due in part to its picomolar affinity.  A system using DHFR-Mtx has 
been used to successfully screen the mammalian proteome for targets of kinase inhibitors.
44
 
Table 1.2. Selected examples of miscellaneous target discovery strategies. 
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Conclusions 
 Target discovery is critical for understanding the mechanism of action of any small molecule.  
Since the majority of known drug targets are proteins, rational drug discovery and development can be 
dramatically improved with the understanding of specific proteins that directly interact with drugs. This 
knowledge can be used to improve drug potency and/or reduce off-target effects, enabling in vitro and in 
vivo assays in which a specific drug-protein interaction is monitored and compared with a variety of 
analogues. Many affinity chromatography methods have been designed to enrich target proteins from a 
normal cell lysate, which are subsequently identified by mass spectrometry-based sequencing. However, 
many drug targets are known to be expressed in low concentrations and possess only moderate target 
affinity. This can be problematic when using the protein detection techniques employed in these assays. 
Molecular biology allows for the selective, controlled overexpression of mammalian proteins in a number 
of different organisms or in vitro, allowing some of the limitations of classic affinity chromatography to 
be overcome.  
The yeast three-hybrid system is a valuable tool that uses of the genetic flexibility of yeast to 
present fused mammalian proteins to tagged drug targets in cellulo. Research directed at improving the 
sensitivity and ease of detection in these assays is described in this thesis. 
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CHAPTER 2.  Improving the Dynamic Range of a Yeast Fluorescent Reporter 
Introduction 
To date, most commercially available yeast hybrid systems do not feature fluorescent reporters 
such as GFP, nor is their use in the literature pervasive. One of the more common reporter types employs 
an essential gene that has been knocked out in the assay strain, and thus reporter activation is required for 
yeast viability. Genes that impart prototrophy (the ability to synthesize a specific compound required for 
growth) are most suitable for yeast hybrid systems, allowing the gene knockout to be compensated by 
growth on appropriate media while the genetic system is being prepared. For example, a yeast strain 
lacking HIS3 is grown in histidine supplemented media to maintain viability until the DBD-bait, AD-
prey, and a reporter vector bearing an AD inducible HIS3 open reading frame are transformed into cells. 
After the hybrid proteins are expressed, cells are then switched to defined media lacking histidine, 
requiring activation of the HIS3 expressing reporter for selection. Several other validated genes involved 
in amino acid synthesis have been used in a similar manner (e.g. LEU2, TRP1, etc).
1
 Plasmids for these 
assays typically use the same set of genes for positive selection of transformants, and care must be taken 
to avoid overlap between plasmid markers and reporters. Auxotrophy in theory reduces false positives 
because reporter expression is required for cell viability.  However, these types of selective reporters do 
not allow for transient expression of Y3H components, which may be preferable to prevent possible 
toxicity from constitutive overexpression of heterologous proteins.
2
 The most prolific non-selective 
reporter used in yeast hybrid assays is the E. coli gene LacZ, which encodes the enzyme β-galactosidase 
(β-gal). This protein catalyzes hydrolysis of the β-glycosidic bond of galactose linked carbohydrates (β-
glycosides). Advantageously, particular chomophores may be linked with galactose, creating a 
chromogenic β-gal substrate to detect LacZ reporter expression. One such substrate, X-gal (bromo-chloro-
indolyl-galactopyranoside), upon β-gal cleavage releases a substituted indole that strains the yeast colony 
blue. If transient expression is desired, a liquid assay of permeabilized cultures from individual colonies is 
necessary. The most common liquid assay substrate, ONPG (o-nitrophenyl β-D-galactopyranoside), 
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releases a yellow ortho-nitrophenol-derived chromophore that can be detected by absorbance 
measurements at 420 nm. Proof of concept experiments with liquid assays have demonstrated that this 
activity is loosely correlated to small molecule-prey affinity in a Y3H assays, although with a low 
dynamic range.
3
 A more sensitive liquid assay uses a chlorophenol red releasing substrate termed CPRG 
(chlorophenolred-β-D-galactopyranoside). Unfortunately this substrate is significantly more expensive 
than ONPG. Fluorogeneic β-gal substrates have also been reported (e.g. fluorescein-di-beta-D-
galactopyranoside).
4
 LacZ is not an ideal reporter for proteomic scale screens since no effective method 
exists to separate expressing and non-expressing cells in mixed cultures, and reporter quantification 
requires cell lysis and time-sensitive, substrate consuming assays. The use of multiple reporters (such as 
HIS3 and LacZ) is not uncommon, as it is an effective strategy to reduce false positives, and the total 
number of colonies required for more labor intensive confirmatory liquid assays. 
Green fluorescent protein (GFP) from Aequorea victoria, along with its many variants, has 
become the default tool to observe gene expression and protein localization in live cells of various 
organisms (reviewed in 
5
), including yeast.
6,7
 The subject of the 2008 Nobel Prize, the 700 bp gene 
encoding this protein can be cloned into most open reading frames often with little consequence to the 
gene products native properties, except the addition of GFP‟s 395/510 absorbance and emission spectra
8
 
(488/510 for the popular spectral variant EGFP). Unlike HIS3 and LacZ, GFP requires no special media 
or substrate for signal detection.  The tripeptide fluorophore (Ser-Tyr-Gly in wtGFP, Gly-Tyr-Gly in 
EGFP),
9
 is induced by higher level structural elements to rearrange, cyclize, and dehydrate to form an 
imidazolin-5-one heterocycle. This is followed by the oxidation of the Tyrosine alpha-beta carbon by O2, 
conjugating the ring system to the tyrosine phenyl ring (Figure 2.1A). The mature fluorophore is 
stabilized and protected in an iconic β-barrel structure, which has a half life of around 7 h in cells.
10
   
Variants of GFP have been used in yeast two-hybrid assays to detect the interactions of proteins,
11-13
 
validating its potential in similar yeast three-hybrid systems. 
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Figure 2.1. Maturations of EGFP fluorophore(A) takes place inside the β-barrel structure and requires no 
cofactors or post-translational modifications. Live cells can be sorted based on the fluorescence intensity 
of expressed EGFP with FACS (depicted in B).  
 
For high throughput use, a fluorescent reporter such as GFP has a major advantage over other 
reporters due to its compatibility with fluorescence-activated cell sorting (FACS).
13-15
 This technology, 
depicted in Figure 2.1B, uses microfluidics to push a cell culture into a single file stream that passes 
through a excitation laser. Emitted fluorescence from each cell can be measured, rather than a batch 
culture measurement. A charge is placed on each cell that is directly proportional to its measured 
fluorescence intensity. Cells are then deflected into different containers based on the associated charge.  If 
a yeast three-hybrid system could differentially trigger expression of a fluorescent reporter protein based 
on interaction of components in cells, this technology would allow live cells to be separated based on the 
strength of a protein-ligand interaction. From here, viable cells could be isolated through growth on solid 
media. Hits can be lysed and their protein encoding plasmids isolated. From here the mammalian gene, 
theoretically the target of the query affinity probe, could be sequenced and/or cloned into other plasmids 
for further validation. 
A. B. 
488nm 
l 
510nm 
l 
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 The Peterson Lab previously used a reporter encoding EGFP to successfully screen a mammalian 
cDNA library and identify tyrosine kinases using a variant of the yeast two-hybrid system known as the 
yeast tribrid system. The employed reporter gene, yEGFP, is a variant of GFP that encodes a mutated 
fluorophore to improve fluorescence quantum yield and was codon optimized for translation in yeast.
16
 
The vector used for this reporter contains eight LexA binding sites and the GAL1-10 divergent promoter, 
taken from the commercial LacZ reporter pSH18-34 (Invitrogen) and inserted into the leucine selectable 
plasmid pBC103.
17
 The resulting plasmid, pDCLryEGFP,
2
 contains a 2-micron origin of replication, an 
ADH1 transcription terminator (downstream of GFP), and a LEU2 selection marking to maintain a high 
plasmid copy number (50-100 copies/cell) in yeast grown in media lacking the essential  amino acid 
leucine (see Figure 2.11). 
  
 
Figure 2.2.  Overlay of flow-cytometric histograms demonstrating fluorescence from pDCLryEGFP 
reporter expression. Each histogram represents 15,000 events, with a gate set to quantify the number of 
highly fluorescent cells from each experiment. Basal fluorescence was quantified with yeast 
transformants harboring empty plasmids (white). Background fluorescence produced with only the 
yEGFP reporter (light gray) and maximal fluorescence with reporter activated by a LexA-B42 fusion 
(dark gray). Adapted from Clark, D.D. and Peterson, B. R. ChemBioChem 2005, 6, 1442-1448. 
  
Even though pDCLryEGFP proved adequate in a yeast tribrid assay to identify the kinase Fyn 
from a human T-cell library,
2
 the limited 20-fold dynamic range made data interpretation difficult. Flow-
cytometry histograms in a one-hybrid assay (Figure 2.1, dark grey), where the “affinity” between the 
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DBD and AD is functionally infinite, shows bimodal EGFP expression. Approximately a third of cells 
express background levels of EGFP, and are likely the result of leaky reporter expression (compare with 
yEGFP reporter alone, light grey)..  This background fluorescence, produced by copies of a non-activated 
plasmid reporter, is significantly greater then basal cell fluorescence (white) and produces cells with 
fluorescence intensity within a decade of LexA-B42 (DBD-AD) activated reporter expression.  This low 
dynamic range would likely contribute to many false positives and/or negatives in a screen using 
components from this system. 
Design and Evaluation of GFP reporter constructs 
 To best take advantage of FACS screening, the fluorescence profiles of control one-hybrid assays 
(as in Figure 2.2) should be improved. To improve the dynamic range, the major goal was to reduce the 
leaky reporter expression. An initial hypothesis posited that cryptic vector enhancer sites of 
pDCLryEGFP induced non-activited EGFP expression. To test this, yEGFP (along with ADHt) was 
cloned into the commercial yeast reporter pSH18-34, replacing the LacZ open reading frame. Plasmid 
pSH18-34 has shown much greater dynamic ranges in reporter expression, and because of its widespread 
use is compatible with many existing commercial yeast two- hybrid systems (and therefore potential 
three-hybrid systems). The resulting plasmid, labeled pSHyEGFP (see Figure 2.10), produced almost a 5 
fold increase in signal to noise ratio (S/N) in a LexA-B42 one-hybrid assay (Figure2.3). This effect was 
almost equally the result of decreased background (45%) and increased fluorescent signal (161%).  
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Figure 2.3. Overlays of flow-cytometric histograms to compare fluorescence generated by reporters 
pDCLryEGFP (A) and pSHyEGFP (B). Each histogram represents 10,000 events with a gate for analysis 
of highly fluorescent cells. The gate begins at the 90
th
 percentile of induced yeast lacking LexA-B42 (red 
histogram). C) Table of relevant statistics taken from histograms. The median signal and coefficient of 
variation (CV) is taken from the gated population of induced cells bearing the complete system (black 
histogram). The signal to noise ratio (S/N) is calculated as the quotient of the signal median and the 
background threshold (90
th
 percentile of the omission control). 
 
Hoping to further improve fluorescence profiles, a series of protocol alterations were designed 
and tested with pSHyEGFP, changing growth and/or induction conditions (data not shown). Although 
these assays helped streamline the protocol, these changes did not yield consistent improvements in 
dynamic range, and unfortunately highlighted problems with reproducibility for these assays. To further 
investigate, the temporal correlation with background fluorescence was specifically monitored. Sequential 
transformations of reporter and the LexA-B42 transcription factor confirmed that increased background 
fluorescence correlated with the time between reporter transformation and the assay itself (Figure 2.4). 
Whereas it was suspected that this background was likely a result of leaky EGFP expression, it was not 
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initially suspected that EGFP significantly accumulated over extended periods in cells were grown in the 
sugar dextrose, which should repress expression of the reporter protein. This finding led to a change in 
strategy. Rather than attempting to reduce leaky EGFP expression, perhaps the resulting fluorescence 
could be limited by increasing the turnover of the protein product. 
 
Figure 2.4. Overlays of flow-cytometric histograms comparing pSHyEGFP one-hybrid assays with 
different plasmid transformation sequences (A,B). Cells were assayed approximately 8 days after the first 
transformation and 4 days after the second. Each histogram represents 10,000 events with gates set as 
described in Figure 2.3. Red and black histograms represent uninduced and induced reporter expression, 
respectively. C) Table of relevant statistics (described in Figure 2.3). 
 
Mateus and Avery previously reported that by fusing the carboxy terminus of CLN2, a tightly 
regulated yeast G(1) cyclin, the half life of GFP in yeast could be reduced from 7 h to 30 min.
10
 The fused 
178 residues are known to contain a number of PEST sequences, which destabilize proteins by expediting 
their polyubiquitination and result in their destruction via the proteosome. I cloned this fragment onto the 
C-terminal end of yEGFP in pSHyEGFP, creating pSHyEGFPpst.  
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Plasmid pSHyEGFPpst was tested with simultaneous transformation for a direct comparison with 
other reporters. Whereas the median signal was reduced to levels below pDCLryEGFP, the background 
fluorescence was reduced substantially (> 90%) compared to pSHyEGFP and pDCLryEGFP, resulting in 
almost another 5 fold increase in S/N (Figure 2.5).  This improvement can be explained by the intended 
reduction in half-life of both the background and induced expressed EGFP-PEST protein. Compared to 
untagged EGFP, the rate of degradation of EGFP-PEST is much closer to the rate of constitutive 
expression of background EGFP(-PEST).  However, the increased degradation of Lex-B42 activated 
EGFP is a detrimental consequence of this increased degradation rate, resulting in the reduction in signal 
fluorescence intensity.  The shorter EGFP-PEST half-life also means that optimal timing between LexA-
B42 induction and flow-cytometric evaluation is increasingly important.  Reporter expression induced by 
the LexA-B42 transcription factor produces a temporary spike in the EGFP-PEST expression rate, but the 
“EGFP boom” degrades shortly after the expression surge has ended. 
   
 
Figure 2.5. (A) Overlay of flow-cytometric histograms from reporter pSHyEGFPpst. Background 
fluorescence from induced yeast lacking LexA-B42 (red) was used to determine the background 
threshold. (B) Table of relevant statistics.  
 
To demonstrate the usefulness of the new reporter to detect protein-ligand interactions, 
pSHyEGFPpst was applied to detect β-estradiol (E2) induced dimerization of human estrogen receptor β  
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ligand binding domains (ERβ(255-509)). The native ligand β-estradiol is known to have nanomolar 
affinity (0.4 nM) and has been shown to promote ligand dependent dimerization in a yeast two-hybrid 
system.
11
 Reporter pSHyEGFPpst expression was activated in a sigmoidal E2 concentration dependent 
manner over a 5 pM-500 nM concentration range, with a picomolar EC50 (Figure 2.5). The high signal 
variability of these three-hybrid assays led to significantly greater CV‟s than in the one-hybrid assay, 
suggesting that median fluorescence may not be the most appropriate statistic for sample comparison. 
Instead, , total counts of cells exceeding an arbitrary threshold of 100 rfu was quantified in each sample. 
Plotted against E2 concentration, the total counts yield a dose-response curve with a greater dynamic 
range than could be obtained by quantification of signal medians. 
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Figure 2.6. Overlay of flow-cytometric histograms demonstrating E2 dependent dimerization of 
ERβ(255-509) monomers. Each histogram represents 10,000 events with gate set to quantify highly 
fluorescent cells (>10
2
 rfu) used in analysis. A) Bait and prey omission controls, treated with 500 nM E2, 
show that each component is necessary for high levels of fluorescence. B) Complete three hybrid-system 
incubated with three representative E2 concentrations. C) Dose-response curve for three-hybrid assay. 
Estradiol treatment concentration is plotted against normalized total count (100% ≈ 2,000 or 3,0000) of 
cells emitting fluorescence >100 rfu. 
 
We also ran similar yeast two-hybrid assays with ligand binding domains (LBDs) of human 
androgen receptor (AR(670-919)) using the ligand dihydrotestoterone (DHT), as well as progesterone 
receptor (PR(682-933)) using progesterone (P4). These assays showed dose dependent reporter 
expression, but omission control assays showed that prey domains were unnecessary to induce reporter 
expression. The B42 independent reporter activation is likely due to a C-terminal transcription activation 
factor domain, termed TAF-2, known to require hormone binding for activity.
18
 Yeast have been used to 
study mammalian steroid receptors through ligand-dependent transcriptional activation,
19-23
 but typically 
A. Omission Controls (500 nM E2) 
EwE 
B. Bait and Prey  
C. 
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these assays use known receptor response elements upstream of the reporter.  A conserved hydrophobic 
domain located in the LBD of AR (between residues 890 and 900) and PR (between 905 and 915) has 
been shown to engage transcriptional machinery in yeast.
24, 25
 The TAF-2 domain of ERβ (between 
residues 535 and 545) was not included in the fragment used for ER dimerization assays. 
 
 
 
Figure 2.7. Overlays of flow-cytometric histograms from PR (P4 CID) and AR (DHT CID) yeast ligand 
dependant two-hybrid assays. Each histogram represents 10,000 events with gate of highly fluorescent 
cells (>100 rfu). A,C) Omission controls with maximum CID treatments and (B,D) representative 
histograms of complete system with added agonist shown.  
 
 
Dose dependent reporter activation with PR LBDs was used to compare pSHyEGFPpst and the 
commercial LacZ reporter pSH18-34 (Figure 2.8). LacZ reporter expression was quantified by measuring 
A. PR Omission Controls (1 mM P4) B. PR, Bait and Prey 
C. AR Omission Controls (10 µM DHT) D. AR, Bait and Prey 
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β-galactoside activity (CRPG colorimetric assay). There was strong correlation between β-gal activity and 
highly fluorescent cell counts over all progesterone concentrations tested, and very similar EC50 values 
were calculated. Beta-galactosidase activity was measured at various times after substrate addition. At 
initial times (10, 20 min), the dynamic range (background from untreated transformants) of both reporters 
was very similar (Figure 2.8), with about 50 fold activation at the highest concentrations. At later times, 
β-gal activity rose to 200-250 fold at the highest treatment concentrations. Both reporters were expressed 
when the prey was omitted, as expected due to the presence of the TAF-2 domain in this construct. 
 
 
Figure 2.8. Overlay of dose-response curves of ligand dependent PR yeast two-hybrid assays treated with 
progesterone. The yEGFP curve is based on counts of cells emitting fluorescence >100 rfu. The LacZ 
curve is based on calculated β-gal activity using a CPRG substrate assay (10 minutes after substrate 
addition). Curves are normalized based on maximum assay readouts (app. 3,000 cells/units of β-gal 
activity = 100%).          
 
Not all reporter modifications produced the desired reporter improvements. Several studies have 
correlated cellular fluorescence intensity of GFP with gene copy number.
14, 26
 Plasmids used for the 
described yeast genetic systems, including reporter pSHyEGFPpst, contain a 2-micron origin and are 
therefore are autonomously replicating episomal plasmids (yEP). The plasmids replicate at a much higher 
rate than chromosomal DNA, but are not under mitotic control during cellular division. Therefore 
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episomal plasmids can reach cellular copy numbers up to 100, but cultures have a high cell to cell copy 
number variability. This instability makes selection even in pure cultures essential.
27
 Fortunately several 
other genetic platforms exist where plasmids can replicate with greater stability.  
It has been reported that more favorable fluorescence profiles in a yeast two-hybrid system result 
from controlling yEGFP copy number, yielding a more precise and consistent signal intensity.
28
 This was 
achieved by integrating yEGFP (and its control elements) into the yeast genome. I integrated 
pSHyEGFPpst into the genome of FY250 to yield a rigorously stable copy number per cell. Unfortunately 
directed integrations are only designed to yield a single copy of the insert, although multiple integrations 
are possible. The majority of plasmid pSHyEGFPpst was integrated by first deleting its 2-micron origin 
(removing its autonomous replication capabilitiy), transforming it into a yeast integration plasmid (yIP), 
termed pSHIPyEGFPpst. Integration at the genomic URA3 locus was performed by restriction digest of 
pSHIPyEGFPpst at single site within its URA3 selection marker (SapI). The linearized plasmid was then 
transformed into yeast FY250. Successfully integrated yeast strains should contain yEGFP and a 
functional URA3 selection marker. A small set of these yeast colonies were separately screened by 
expression of LexA-B42 (Figure 2.5A,B). Integrations maintained the low background of episomal 
pSHyEGFPpst. However, the integrated reporter produced, at best, 40% of the median signal yielded by 
its episomal version. Discrete colony to colony variation was likely a result of multiple integration events.  
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Figure 2.9. Overlays of flow-cytometric histograms of integrated reporter strains FY250yEGFPpst1 (A) 
and 2 (B), and plasmid reporter pDCUdyEGFP (C). Background fluorescence from induced yeast lacking 
LexA-B42 (red) was used to determine the background threshold, as described previously. (D) Table of 
relevant statistics.     
 
In a separated strategy, it was hypothesized that signal intensity might be increased by increasing 
yEGFP copy number. It has been reported that higher copy numbers (up to 150) could be maintained in 2-
micron plasmids with deficient selection markers.
29
 An N-terminal deletion in the URA3 promoter, termed 
URA3-d,
29
 yields decreased expression rates of the selection gene, and in turn lower concentrations of the 
protein product orotidine 5-phosphate decarboxylase. The result is a reduction in de novo synthesis rates 
of uracil per gene, and thus yeast cells are under selective pressure to have high copy numbers of URA3-d 
to compensate. I replaced the LEU2 marker in pDCLryEGFP with URA3-d and tested the plasmid, named 
pDCUdyEGFP, with the LexA-B42 one-hybrid assay (Figure 2.5C). A 74% increase in the median 
fluorescence intensity was gained from switching from LEU2 to Ura3-d, but still only 67% of the median 
signal of pSHyEGFP. Unfortunately the background threshold increased by almost 80%, to give a slightly 
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reduced S/N compared to pDCLryEGFP. It should be emphasized that this strategy was carried out on the 
plasmid reporter lacking the PEST ubiquitination tag. 
Conclusions 
The results presented here demonstrate destabilization of EGFP has a positive effect on signal to 
noise ratios in yeast hybrid assays. This effect is mainly seen in a significant reduction in background 
fluorescence caused by constitutive leaky expression of the reporter. This improved reporter may be 
useful for more complex yeast reporter assays, as demonstrated by the β-estradiol dependent dimerization 
of estrogen receptor β. To my surprise yeast copy number did not have a significant positive effect on 
results of the described yeast one-hybrid assay. 
This reporter should be tested in control yeast two- and three-hybrid screens with a cDNA library. 
It is yet to be seen whether a threshold value can be assigned that effectively distinguishes target 
protein(s) from the rest of a library, which is essential for selection using FACS. As is common with β-
galactosidase reported screens, the simultaneous use of a prototrophy restoring reporter gene (e.g. HIS3) 
could be investigated. 
Experimental 
General: Standard techniques for plasmid construction and microbial maintenance/manipulation 
were employed.
30
 PCR for plasmid construction was preformed with Phusion Flash PCR Master Mix 
(New England Biolabs (NEB)) following the manufacturer‟s instructions. Reagents for plasmid 
construction and PCR were purchased from the following sources: DNA oligonucleotides (Integrated 
DNA Technologies (IDT)); restriction endonucleases ,T4 DNA ligase, T4 DNA polymerase and Phusion 
DNA polymerase (NEB); and DNA isolation and purification kits (Qiagen and Zymo Research). 
Microbiological media (Luria broth (LB), Brent Supplement Mixtures (BSM), yeast nitrogen base, carbon 
sources, yeast extract, and peptone) were from Difco and qBiogene. Prepoured solid yeast selection media 
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was purchased from Teknova. DNA sequences were confirmed by automated dideoxynucleotide 
sequencing at KU Medical Center Biotech Support Facility or ACGT. 
Bacterial and Yeast Strains:  Escherichia coli DH5-α (Invitrogen) was employed for plasmid 
construction. Saccharomyces cerevisiae FY250 (MATα, ura3-52, his3 200, leu2 1, trp1 63) (a gift of 
Prof. M. Ptashne (Memorial Sloan-Kettering) was employed for yeast hybrid assays. 
Plasmid Construction:  Reporter plasmid pSHyEGFP is a URA3 selectable, episomal plasmid 
containing 8 LexA binding sites (LexAop) and GAL1-GAL10 (Gal1pr) divergent promoter upstream of 
yEGFP and the yeast transcription termination sequence yADHt (see Figure 2.10).  This plasmid was 
constructed using the SLIC technique reported by Li and Elledge
31
, in part because necessary restriction 
sites in the vector were not available. The vector backbone and upstream control elements was amplified 
from pSH18-34
30, 32
 using PCR primers (pSH fwd:  CATAACGCAGGAAAGAACATGTGAGCA; pSH 
rvs:  GCACTTTTCGGCCAATGGTCTTG). Reporter gene yEGFP and yADHt were amplified from 
pDCLryEGFP
2
 using PCR primers (VHR-yEGFP fwd:  GACCATTGGCCGAAAAGTGC 
ATGTCTAAAGGTGAAGAATTATTCACTG; VHR-ADHt-yEGFP:  ATGTTCTTTCCTGCGTTATG 
GCATGCCGGTAGAGGTGT) that flank the insert with 20 bp homology to the vector. Cloning was 
performed following the protocol as reported,
31
 with scaled down 30 min exonuclease chew-back 
reactions using approximately 500 µg vector and insert PCR products in 10 µL reactions. 
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Figure 2.10.  Plasmid map of pSHyEGFPpst. The 2-micron ori and URA3 selection marker, shown in 
gold, maintain plasmid copies in yeast.  The pBR322 ori and AmpR selection marker, shown in red, 
maintain plasmid copies for propagation in E. coli. Plasmid pSHyEGFP (7091 bps) lacks the Cln2-PEST 
(green, lined box) region of the reporter gene, but otherwise is identical. Plasmid pSHIPyEGFPpst (5386 
bps) lacks the 2-micron ori, but is otherwise identical to pSHyEGFPpst. 
 
 Plasmid pSHyEGFPpst is a variant of pSHyEGFP with a C-terminal fusion of a 178 residue 
fragment from Cln2. The CLN2 fragment was amplified from purified yeast genomic DNA using PCR 
primers (VHR-PEST fwd:  CCCATGGTATGGATGAATTG GCATCCAACTTGAACATTTCGAG; 
VHR-PEST rvs:  GGCGAAGAAGTCCAAAGCTTGTCGAC 
CTATATTACTTGGGTATTGCCCATAC) that flanked the insert with 20 bp vector homology. The PCR 
fragment was cloned into XhoI digested pSHyEGFP using SLIC. 
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Figure 2.11.  Plasmid map of pDCLryEGFP. In pDCUdyEGFP (6994 bps) the LEU2 selection marker 
(gold arrow) is replaced with a URA3-d selection marker, but otherwise is identical to pDCLryEGFP. 
 
Plasmid pDCUdyEGFP is a derivative of pDCLryEGFP (see Figure 2.11) with a deficient URA3 
selection marker (URA3-d). Plasmid pDCLryEGFP minus its LEU2 selectable marker (and controlling 
elements) was amplified by PCR with primers (pDCLr-LEU2 fwd:  
ATTAATTCTCATGTTTGACAGCTTATCATCGG; pDCLr-LEU2 rvs:  
TTCTTGAAGACGAAAGGGCCTCGT). Amplification of the Ura3-d selectable marker was carried out 
with PCR primers (Ura3d fwd:  GGCCCTTTCGTCTTCAAGAA ATAACCCAACTGCACAGAACAA; 
URA3d rvs:  TGTCAAACATGAGAATTAAT CCCGGGTAATAACTGATATAATTAAATTGAAG) 
that flanked each end of the product with 20 bp of homology to the ends of PCR product pDCLryEGFP-
LEU2. The two PCR products were cloned together using SLIC.   
Plasmid pSHIPyEGFPpst was constructed using an intramolecular SLIC reaction to delete its 2- 
micron origin. Amplification of pSHyEGFPpst minus the entire 2-micron origin sequence was carried out 
using PCR primers (pSHIPyEGFP fwd:  
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TCGTCTTCAAGAATTCTCATGTTTGACAGCTTATCATCGA; pSHIPyEGFP rvs:  
GTCAAACATGAGAATTCTTGAAGACGAAAGGGCCT) that flanked the produce with 20 bp of 
homology to allow sequence specific circularization following T4 polymerase treatment. 
Yeast Control One-Hybrid Assays with Flow-Cytometry:  Yeast one-hybrid assays are 
typically used to discover new protein-DNA interactions. For this study, this system was employed for the 
quantitative comparison of reporter constructs using the heterologous transcription factor LexA-B42 
(previously inserted into the HIS3 selectable expression vector pAM423).
33
 Plasmid pAM423 LexA-B42 
(previously constructed)
33
 was cotransformed with a reporter plasmid (pDCLryEGFP, pSHyEGFP, 
pSHyEGFPpst, pDCUdyEGFP, or SapI cut pSHIPyEGFPpst  using the LiAc/SS carrier DNA/PEG into 
frozen competent yeast
34
  on appropriate solid yeast selection media (SD-His-Leu + 2% glucose or SD-
His-Ura + 2% glucose).  
From selective plates bearing both components of the one-hybrid system, multiple (2-8) large 
colonies were picked and grown (30 °C incubation with shaking, 300rpm) to saturation (app. 18 h) in 
selective 2% glucose media (3 mL). Colonies were pooled for episomal reporters, but for the yIP reporer 
pSHIPyEGFPpst, picked colonies were kept separate, due to possible variability of integration.  Aliquots 
of saturated cultures were pelleted and washed once with PBS, then diluted 1:4 in selective 1% raffinose, 
2% galactose induction media (400 µL) and grown for 10 h before quantification. Resultant reporter gene 
fluorescence intensity was measured by flow-cytometry. Cell viability was monitored concurrently with 
nuclear staining (using 10 nM propidium iodide).   Flow-cytometry was performed on an Accuri C6 
Flow-Cytometer excited with a 488 nm laser and collected with a 530 +/-15 nm emission filter (GFP) and 
a >670 nm emission filter (propidium iodide). These assays were preformed in duplicate from two 
different sets of colonies which produced similar results.  Histograms and statistics are shown from one of 
these duplicates.  
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For sequential transformations, either pSHyEGFP or pAM423 LexA-B42 was transformed into 
frozen competent yeast and plated onto appropriate selection media. Multiple pooled colonies were 
inoculated into appropriate liquid yeast selection media (3 mL; SD-His-Ura + 2% glucose) and incubated 
with shaking (30 °C, app. 18 h) to saturation. The resulting cultures were then transformed with the other 
plasmid using the Quick and Easy LiAc/SS carrier DNA/PEG method
35
 and plated on appropriate 
selection media. 
Yeast Three-Hybrid Assays with Flow-Cytometry:  Frozen competent yeast FY250 were first 
transformed with reporter plasmid pSHyEGFP and plated on selective solid media (SD-ura + 2% 
glucose). Multiple large colonies were pooled and inoculated into appropriate liquid selection media and 
grown to saturation (3 mL). Saturated cultures were diluted 1:6 in liquid selection media (10 mL) and 
grown to mid-log phase (app. 4 h) and resuspended in 200 µL sterile water. An aliquot of yeast 
concentrate (100 µL) was then transformed with previously constructed pAM423 LexA-ERβ(255-509) 
and pJG45 ERβ(255-509)
36
 using the “Quick and Easy” LiAc/SS carrier DNA/PEG method
35
 and plated 
on yeast solid selective media (SD-His-Trp-Ura + 2% glucose). From this plate multiple large colonies 
were pooled and grown to saturation in appropriate liquid selection media. Aliquots (100 µL) were 
pelleted and washed once with PBS, then diluted 1:4 in selective 1% raffinose, 2% galactose induction 
media. These cultures were grown for 4 h and then treated with the various concentrations of β-Estradiol 
(0, 5 pM, 10 pM, 50 pM, 500 pM, 1 nM, 5 nM, 10 nM, 50 nM, 100 nM, 500 nM). Resultant reporter gene 
fluorescence intensity was measured by flow-cytometry (described previously). These assays were 
preformed in triplicate from different sets of colonies that produced similar results. Histograms and 
statistics are shown from one run. 
Cells for the androgen and progesterone receptor homodimerization assays were prepared 
similarly to ER dimerization assays. Plasmids pAM423 AR(670-919), pAM423 PR(682-933), pJG4-5 
AR(670-919), and pJG4-5 PR(682-933) were previously constructed.
37
  Sequencing (after running the 
assays) revealed an unexpected and unintended P906S mutation in the progesterone receptor (PR) 
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fragment used.  For PR dimerization, cells were treated with various concentrations of progesterone (0, 
0.1 µM, 0.5 µM, 1 µM, 5 µM, 10 µM, 100 µM, and 1 mM). For AR dimerization, cells were treated with 
various concentrations of dihydrotestosterone (0, 0.1 nM, 0.5 nM, 1 nM, 5 nM, 10 nM, 50 nM, 100 nM, 
500 nM, 1 µM, 5 µM, 10 µM).  These assays were preformed in duplicate from the same set of colonies 
that produced similar results. Histograms and statistics are shown from one run.   
Yeast Three-Hybrid Assays with Microtiterplate β-galactosidase Assays:  Cells were 
prepared, induced, and treated just as cells for flow-cytometry, except reporter plasmid pSH18-34 was 
used rather then pSHyEGFPpst. The resulting treated cultures (400 µL, SD-Trp-Leu-Ura + 1% raffinose + 
2% galactose) were harvested, resuspended in Z lysis buffer
38
 (additionally containing 0.1% SDS, 200 
µL), and transferred to a 96-well plate. The absorbance at 570 nm (OD570cells) was measured to 
determine cell density, followed by the addition of the substrate chlorophenol red-b-D-galactopyranoside 
(15 mM, 30 µL) in sodium phosphate buffer (0.1 M, pH 7.5). The plate was shaken at 30 °C with periodic 
(10 min, 20 min, 40 min, and 60 min) absorbance measurements at 570 nm (OD570). β-Galactosidase 
activity was calculated as follows: Activity = 1000*(OD570-OD570cells-Blank1)/(TIME*(OD570cells-
Blank2).
38
 The Blank1 value represents the absorbance at 570 nm of chlorophenol-red-b-
galactopyranoside alone (30 µL). The Blank2 value corresponds to the absorbance at 570 nm of Z lysis 
buffer alone (150 µL). The TIME value was expressed in minutes 
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CHAPTER 3.  Investigations into Modifying the Valency of Streptavidin for an Improved Yeast 
Three-Hybrid Platform 
Introduction 
The extreme affinity of streptavidin for its natural ligand biotin (Kd ≈10
-14 
M)
1, 2
 has found utility 
in many different life science applications, and serves as a model for noncovalent protein-ligand 
interactions.
3
 This interaction is stable under a variety of typically disruptive conditions, such as heat, 
denaturation, pH, and proteolysis.
3
 Biotin can easily be tagged to a variety of molecules, often with little 
effect on their biological properties.
4
 Streptavidin can also be fused to other proteins or conjugated to 
lower MW molecules
4
, although its large size may be problematic for some applications. These features 
make streptavidin-biotin suitable for a number of detection and separation techniques. Detection typically 
entails the biotinylation of the compound of interest and the conjugation of streptavidin to the labeling 
system (an enzyme, fluorophore, etc). For separation or purification of biotinylated molecules, 
streptavidin is often immobilized to a solid support (e.g. agarose) and captures the biotin moiety from 
solution. The work presented here wass based on the hypothesis that the unmatched affinity of biotin-
streptavidin might be used to improve existing yeast three-hybrid systems. A biotin-streptavidin anchor 
moiety would also be attractive for its compatibility with the many affinity chromatography methods that 
use biotinylated small molecules.  
Streptavidin is an app. 60-70 kDa
4
 homotetrameric, tetravalent protein secreted by the bacteria 
Streptomyces avidinii,
1
 possibly as a natural defense to deprive competing organisms of the cofactor 
biotin. Each subunit of streptavidin consists of an essential 126 residues
5
 that secondarily form eight 
antiparallel β-strands with short connecting loops, and then folds into a classic up and down β-barrel.
6
 
Each subunit is said to bind one biotin, but more accurately, a pair of subunits share two biotins. Each 
monomer largely encapsulates a single biotin towards the end of its barrel, and contributes all of the 
hydrogen bonds with that ligand. However the conserved W120 from the loop of a neighboring subunit 
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contributes significantly to the hydrophobic pocket
7
 (Figure 3.1A), enhancing biotin binding by up to 8 
orders of magnitude. A functional dimer is formed by an almost perpendicular pair of monomers that use 
each other‟s W120 residues. A structural dimer of dimers completes the quaternary structure, orchestrated 
in an antiparallel fashion and interfaced by only a handful of residues (Figure 3.1C). Streptavidin is 
structurally and functionally very similar to the protein avidin,
3
 found in chicken egg white. Chicken 
avidin actually has a slightly higher binding affinity,
8
 but is notorious for nonspecific binding due to its 
native glycosolation pattern (mannose and N-acetylglucosamine) and a pI ≈ 10
4
. Avidin also contains 
structural disulfide bonds that are not likely to be stable in cytoplasm. Therefore streptavidin is preferred 
for most applications, although an acidic (pI ≈ 4.7), non-glycosolated variant of avidin has been 
constructed to overcome some of avidin‟s limitations.
9
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Figure 3.1. Selected views of X-ray crystal structure of tetrameric core streptavidin complexed with 
biotin (PDB: 1SWE).
10
 A) Within a functional dimer (solid red and blue) two W120 residues (top, shown 
in sticks) enhance biotin affinity. C) Structural dimer (blue and green) interfaces are more extensive. 
Selected residues that have been mutated to disrupt oligimerization are shown in sticks. The biotin 
binding pocket involves a hydrogen bonding network (B) and a hydrophobic pocket (D). 
 
The biotin binding pocket of native streptavidin is highly optimized, and all reported ligand 
pocket mutants have reduced biotin affinity.
11
 At the binding site, there a total of eight hydrogen bond 
contacts with streptavidin residues Asn23, Tyr43, Ser27, Ser45, Asn49, Ser88, Thr90 and Asp128 
(Figure3.1B).
5
 These hydrogen bonds cover all the non-carbon atoms of biotin, concentrated at the ureido 
ring. Paradoxically, biotin is relatively hydrophobic and likewise a hydrophobic binding pocket is 
maintained by four conserved tryptophan side chains (W79, W92, W108, and W120 from a neighboring 
monomer, Figure 3.1D).
12
 In the absence of biotin, five water molecules mimic biotin,
5
 but biotin binding 
induces conformational changes that stabilize a complete streptavidin.
13
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Despite the utility of the streptavidin-biotin interactions, many modifications have been made to 
improve its compatibility with a specific application (reviewed in 
11, 14
). For some precipitation or delivery 
strategies, a lower affinity streptavidin (e.g. T76R and V125R) allows reversible biotin binding under 
mild conditions.
15, 16
 An E51K, N118K mutant has been conjugated to polymers that change conformation 
in response to specific stimuli (pH change, light, temperature), creating steric hindrance that induces the 
capture or release of biotin.
16
 However, most modifications aim to adjust the valency of streptavidin. For 
some detection systems, tetravalency serves to amplify the signal produced by streptavidin fusions.
4
 For 
other systems, tetravalency causes detrimental aggregation of fused proteins. Investigations into altering 
streptavidin typically aim to disrupt tetramerization through interface mutations, or to cross link 
monomers together so that they may be individually engineered. A monomeric (and therefore 
monovalent) streptavidin should effectively tackle aggregation problems, and have the additional benefit 
of decreasing the size of a streptavidin tag by 75%, reducing the risk of steric disturbance of other parts of 
the assay. A fully monomeric streptavidin has been reported, but unfortunately its biotin affinity is 
substantially reduced (Kd ≈ 1.3 × 10
-8
 M). This was achieved by knocking out two biotin hydrogen bond 
contacts (T90A, D128A).
17
 The same group later achieved effective monomerization with a set of 
monomer interface mutations (T76R, V125R, V55T, and L109T), but with further reduced biotin 
affinity.
15
 Attempts have also been made to preserve the functional dimers, but disrupt tetrmerization 
through an H127A mutation and a loop (G113-W120, between β-strands 7 and 8) deletion.
18
 These 
mutations did result in a soluble dimeric streptavidin, but biotin affinity was again dramatically reduced 
(Kd ≈ 1.5 × 10
-7
 M). Interestingly, biotin was required for dimerization of this mutant. Reduced binding 
affinity in these mutants likely results from the disruption of the hydrophobic binding pocket afforded, in 
part, by a neighboring subunits W120 on the native tetramer. Similar efforts with chicken avidin have 
yielded analogous results.
19, 20
 
Another approach to produce a monovalent streptavidin requires combining the subunits of 
streptavidin into a single polypeptide chain, encoded on a single gene. This would allow individual 
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monomers to be modified through directed mutations, and create a pseudo-heterotetramer of monomers 
with different biotin affinities. Unfortunately neither the native N- or C-termini of any monomer fold into 
positions near subunit interfaces. Therefore the design of a linker connecting native subunit termini‟s has 
never been considered. However, the native termini do fold into a proximity and orientation that allows a 
short, flexible peptide linker to form a β-turn between the native first and last strand of each subunit. 
From here, new termini could possibly be designed which allow fusion with minimal effect on protein 
folding.  
Thus far, the only successful design of a single chain dimer of streptavidin uses a GGGS native 
termini linker, and fuses the 7/8 strand loop of one subunit to 4/5 loop of its partner.
21
 The engineered 
polypeptide‟s N-terminus is residue 116 of the native monomer and ends C-terminally with residue 68 of 
a second subunit. A new amide bond between residues 115 and 69 of the linked monomers is created 
(Figure 3.2). This design fuses monomers of structural dimer, whose subunits do not rely on each other‟s 
W120 for biotin affinity. This single-chain dimer (SCD) also includes a W5K (W120K in the native 
topology) to prevent functional dimerization (pseudotetramerization). In theory this would mean that 
neither biotin of the „dimer‟ would possess a neighboring W120 necessary for extreme biotin affinity. 
However, even with this mutation, pseudotetramerization was highly favored in the presence of ligand. 
Unsurprisingly, biotin affinity was significantly reduced (Kd ≈ 6.7× 10
-6
 M), but the ligand derivative 
biotin 4-fluoroscein unexpectedly maintained a high affinity (Kd ≈ 1.2 × 10
-10
 M for both wild-type 
streptavidin and the SCD). 
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Figure 3.2. View of streptavidin X-ray crystal structure (PDB: 1SWE) with linkers in SCD streptavidin 
represented by black lines. The GGGS linker (bottom) between the native N- and C- termini (shown in 
green stick) allows direct fusion between two monomers (top) between S69 and T115 (shown in brown 
stick). New N- and C- termini (E116 and G68, highlighted in yellow) are created. 
 
Similar aims with chicken avidin have been pursued with greater success. Circular permutations 
of avidin establish new termini between at the 4/5 loop and the 5/6 loop.
22
 The 4/5 subunit permutation 
was shown to maintain biotin affinity, while the 5/6 permutations forfeited a slight affinity reduction. 
These permutations were fused with an SGG linker, creating dcAvd.
22
 This design was taken further by 
fusing duplicates of dcAvd with a 12 peptide serine and glycine rich linker.
23
 The resulting scAvd 
subunits maintain wild-type like biotin affinity. To demonstrate the usefulness of a single-chain 
„tetramer,‟ biotin affinity was weakened in one of the biotin binding domains to generate a dual-affinity 
streptavidin (dadcAvd). This scheme has yet to be replicated in streptavidin, but due to their structural 
similarities, this inspires confidence that a single chain streptavidin is possible. Because of internal 
disulfide bonds in avidin, the use of avidin in yeast genetic systems is problematic. 
In the context of yeast three-hybrid systems, a reduced streptavidin valency might improve assay 
sensitivity and dynamic range for the majority of the mammalian proteome. This is based on the 
hypothesis that protein aggregation caused by streptavidin‟s tetravalency would sterically hinder certain 
ligand-prey interactions, thus preventing reporter expression.  The reduced biotin affinity of existing 
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monovalent and divalent streptavidin mutants negates the major potential advantage of biotin-streptavidin 
three-hybrid systems over existing anchor moieties (e.g. Methotrexate-DHFR).  
Design and Evaluation of New Streptavidin Constructs 
To reduce the valency of streptavidin tetramers, my goal was to convert the four subunit complex 
from a homotetramer of high affinity biotin binding monomers to a heterotetramer of subunits with 
normal biotin affinity and those with negligible biotin affinity.  Howarth et al. have reported the creation 
of a triple mutant N23A, S27D, S45A subunit that maintained the quaternary structure of wild-type 
streptavidin.
24
 Homotetramers of the “dead” mutant yield “negligible biotin binding” (app. Kd=1.2 × 10
-3
 
M).
24
 I recreated this triple mutation in core wild-type streptavidin (SAwt) with a single round of PCR 
mutagenesis, terming it SAnb (streptavidin “non-binding”).  
Howarth et al. combined the purified protein subunits of wild-type and mutant streptavidin, and 
were able to differentially elute the different combinations of tetramers with affinity chromotrography.
24
 
Unfortunately streptavidin is not yeast cell permeable and yeast hybrid assays require LexA fusions to be 
present in the nucleus of living cells. The idea of co-expressing wild-type and LexA fused mutant 
streptavidin monomers was entertained. However this strategy would generate a statistical mixture of 
mono- to tretravalent streptavidins, each with a different number of LexA DBDs.  
I instead decided to try to combine subunits of SAwt and SAnb, first into a dimer, using the 
circular permutation method described by Aslan et al. (described earlier, Figure3.3).
21
 Since maintaining 
biotin affinity in the active subunits was of utmost importance, the W120K mutation was omitted. I 
recreated the described 5>4 and 8>7 circular permutations (cp) with SAwt and SAnb, labeling them 
according their new N- and C-terminal β-sheets (cpSA87 and cpSA54; cpSAnb87 and cpSAnb54).  
Permutations of „alive‟ (A) and „dead‟ (D) monomers were then fused in different combinations to yield 
single-chain dimers that are theoretically unable to bind biotin (dSADD), bind a single biotin (dSADA), or 
bind two biotin ligands (dSAAA). 
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Figure 3.3. Topology map of core streptavidin monomer (A) and SCD (B), with identical coloring of β-
strands. Residues involved in biotin binding are identified (H-bonding: grey boxes, Hydrophobic 
contacts: red boxes), and the three residues mutated to create SAnb (blue arrows). Chainsaws indicate 
where new termini are created in the circular permutations. 
 
To test these constructs, I employed a yeast three-hybrid system with the modified EGFP reporter 
pSHyEGFPpst. All created streptavidin mutants are designed to have tetramerization (or pseudo-
tetramerization) properties similar to wild-type streptavidin, and therefore should form tetramers with 
each other and/or wild-type streptavidin monomers. A yeast three-hybrid system was proposed to confirm 
this interaction by expressing a fluorescent protein that can be quantified easily by flow-cytometry. Up to 
two versions of streptavidin were tested against one another, fusing one construct to the DBD and another 
to the AD of a split transcription factor. 
Using this system, the LexA-SAwt was tested separately against B42 fused SAnb, circular 
permutations cpSA87, cpSA54, and the fusion of these permutations dSAAA (Figure 3.4). Each variant 
tested produced significant fluorescent populations above the set threshold, indicting tetramer formation 
in each case. Unfortunately, the smaller fluorescent populations in the circular permutations also suggest 
reduced affinity for oligmerizaiton, more so with dimeric fusion of the two. Since it is known that biotin 
87 54 
A. B. 
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enhances tetramerization of streptavidin,  the induction media (containing 10 nM biotin
25
) was spiked 
with 1 µM biotin. Excess biotin had little effect on SAwt and SAnb (not shown), but significantly 
increased EGFP expression with bait cpSA87, cpSA54 and dSAAA. This result also suggests that the 
circular permutations have reduced affinity for biotin. To further test this, cpSAnb54 was fused to B42 and 
assayed with LexA-fused cpSA87 and cpSAnb87. These combinations failed to yield highly fluorescent 
counts of even 1,000 (10 nM biotin), and the addition of 1 µM biotin failed to increase the activated 
populations (histograms not shown). 
 
 
Figure 3.4. A) Overlays of flow-cytometric histograms of three-hybrid assays with SA variants (bait) and 
wtSA (prey). Untreated assays contain 10 nM biotin present in media. B) Table of total counts of cells 
generating EGFP fluorescence greater than 100 rfu.   
   
We later assayed the single-chain dimers for their ability to homodimerize (forming a 
pseudotetramer) after fusing dSAAA, dSADA and dSADD to LexA and dSAAA to B42 (Figure 3.5). 
Similarly, histograms indicted that homodimers were forming and in AA and DA that was enhanced by 
A. 
B. 
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excess biotin, but with even less affinity then the monomers tested previously. As expected, dSADD 
dimerization was not enhanced by excess biotin due to its negligible biotin affinity. 
 
 
Figure 3.5. A) Overlays of flow-cytometric histograms of three-hybrid assays with dimeric SA variants 
(bait) and variant dSAAA (prey). Untreated cells (red) contain 10 nM biotin, treated cells (blue) are spiked 
with 1 µM biotin. B) Table of total counts of cells that generated GFP fluorescence above 100 rfu. 
 
Construction of a single-chain streptavidin was attempted and a few permutations were 
completed. These genes fuse two dSA with a 12 residue SG rich linker.  Unfortunately, tests of these 
constructs with a previously described yeast tribrid system
26
 yielded inconclusive histograms.     
 
Conclusions 
 The results described here indicate that the streptavidin circular permutations first reported by 
Aslan et al. possess reduced biotin affinity, even without the reported W120K mutation.  This is inferred 
A. 
B. 
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because increased concentrations of biotin are necessary to produce EGFP reporter fluorescence 
comparable to wild-type streptavidin in otherwise identical yeast genetic systems. Fusions of these 
permutations were used to create single-chain dimeric streptavdins with theoretical valencies of 0, 1 and 
2. Control yeast three-hybrid assays suggest that oligimerization affinity of non-valent dimeric streptavdin 
is reduced compared to monovalent and divalent single-chain dimers, as increased biotin concentrations 
marginally increase reporter fluorescence with mono- and divalent streptavdins, but not with non-valent 
dimers. 
 In order to create a monovalent, monomeric streptavidin, novel pairs of circular permutations 
should be designed and investigated. At least one of these permutations should have wild-type biotin 
affinity, and the permutations should have the ability to be fused, possibly with peptide linkers, in a way 
that does not alter secondary or tertiary structure. Theoretically two different fusions will need to be 
made, one to create a single-chain dimer and the other to link homodimers of this construct, thus creating 
a single-chain tetramer.      
Experimental  
General: Standard techniques for plasmid construction and microbial maintenance/manipulation 
were employed.
27
 PCR for plasmid construction was preformed with Phusion Flash PCR Master Mix 
(New England Biolabs (NEB)) following the manufacturer‟s instructions. Reagents for plasmid 
construction and PCR were purchased from the following sources: DNA oligonucleotides (Integrated 
DNA Technologies (IDT)); restriction endonucleases ,T4 DNA ligase, T4 DNA polymerase and Phusion 
DNA polymerase (NEB); and DNA isolation and purification kits (Qiagen and Zymo Research). 
Microbiological media (Luria broth (LB), Brent Supplement Mixtures (BSM), yeast nitrogen base, carbon 
sources, yeast extract, and peptone) were from Difco and qBiogene. Prepoured solid yeast selection media 
was purchased from Teknova. DNA sequences were confirmed by automated dideoxynucleotide 
sequencing at KU Medical Center Biotech Support Facility or ACGT. 
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Bacterial and Yeast Strains:  Escherichia coli DH5-α (Invitrogen) was employed for plasmid 
construction. Saccharomyces cerevisiae FY250 (MATα, ura3-52, his3 200, leu2 1, trp1 63) (a gift of 
Prof. M. Ptashne) was employed for yeast hybrid assays. 
Plasmid Construction:  Streptavidin triple mutant N23A, S27D, S45A was made by PCR 
mutagenesis from pPA1 LexA-SA, a yeast expression plasmid containing a 2-micron origin of 
replication, a LEU2 selection marker and a GAL1 promoter (see Figure 3.6). Plasmid pPA1 LexA-SA was 
constructed by ligation of EcoRI, XhoI digested pPA1 LexA and MfeI, XhoI SA(13-139) digested PCR 
fragment, amplified from pPA1 T7SA-LexA.
26
  
 
Figure 3.6.  Plasmid map of pPA1 LexA-SA. All streptavidin LexA- fusions were cloned into pPA1 
LexA, replacing SAwt. 
 
To make all mutations in one round of mutagenesis, approximately half of pPA1 LexA-SA was 
amplified with PCR primers (SAtko fwd: 
CGTGACTGCAGGCGCCGACGGCGCCCTGACCGGAACCTACGAGGCTGCCGTCGGCAA; SAtko 
w/fwd:  CGGTATCATTGCAGCACTGG) designed to create mutations S27D and S45A. The other half 
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to the plasmid was amplified with PCR primers (SAtko rvs: 
CGTCGGCGCCTGCAGTCACGATGAAGGTATCGCCGAGCTGAGCGTACCAGGTGCCGGTGA 
and SAtko w/rvs: CCAGTGCTGCAATGATACCG) designed to create mutations N23A and S27D and 
flank the product with 20-bp homology to the other PCR product. These primers also create a silent PstI 
restriction site to facilitate screening. The PCR products were joined using SLIC
28
  to yield pPA1 LexA-
SAnb. 
Circular permutations cpSA87, cpSA54 fused to LexA were made with a two insert SLIC reaction. 
For permutation cpSA87, core streptavidin residues 116-139 were amplified by PCR primers (SC1 fwd: 
CGCAACGGCGACTGGCTGGAATTC GAGGCCAACGCCTGGAAGTCC; SC1 rvs:  
GCCGGCCTCGTCGGATCCACCACC GGAGGCGGCGGACGGCTT) that flanked the product with 5‟ 
20-bp homology to vector pPA1 LexA and 3‟ GGGS linker + SA residues 1-4. Residues 1-115 were 
amplified by PCR primers (SC2 fwd:  GGTGGTGGATCC 
GACGAGGCCGGCATCACCGGCACCTGGT; SC2 rvs:  GAAGTCCAAAGCTTCTCGAG TCA 
TCCGGAGGTGGTGCCGGAGGTCAGCAGCCACTG) that flanked the product with 5‟ GGGS linking 
and 3‟ BspEI site + stop codon (tca) + 20-bp homology to vector pPA1 LexA. These two inserts were 
cloned into EcoRI, XhoI cut vector pPA1 LexAstop with SLIC. Similarly for cpSA54, streptavidin 69-139 
were amplified with PCR primers (SC3 fwd: CGCAACGGCGACTGGCTGGAATTC 
TCCGGAACCGCCCTCGGTTGGACGGTGGCC; SC3 rvs: GGATCCACCACC 
GGAGGCGGCGGACGGCTTCACCTT) that flanked the product 5‟ 20-bp vector homology + BspEI site 
+ 3‟GGGS linker. Residues 1-68 were amplified with PCR primers (SC4 fwd: 
TCCGCCGCCTCCGGTGGTGGATCC GACGAGGCCGGCATCACCGGCACC; SC4 rvs: 
CGAAGAAGTCCAAAGCTTCTCGAG TCA GCCGTCGGTGGCCGGGGCGCTGTC) that flanked the 
product with 5‟ SA residues 136-139 + GGGS linker and 3‟ 20-bp vector homology. These two inserts 
were cloned into EcoRI/XhoI cut vector pPA1 LexAstop with SLIC. Circular permutations cpSAnb87 and 
cpSAnb54 were made from template pPA1 LexA-SAnb using the same primers and protocol. 
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Streptavidin single-chain dimers (dSA) fused to LexA were created by inserting cpSA(nb)54 
downstream of SA(nb)87 in pPA1 LexA. Constructs cpSA54 and cpSAnb54 were amplified with 
sequencing plasmid PCR primers (5‟pPA1 LexA: CATTGAAGGGCTGGCGGTT; 3‟pPA1 LexA: 
GACAACCTTGATTGGAGACTTGACC). The PCR product was digested with BspEI, XhoI and ligated 
into BspEI, XhoI digested pPA1 LexA-cpSA87 or pPA1 LexA-cpSAnb87. 
Converting the streptavidin constructs from LexA fused bait to B42 fused prey was performed by 
ligating the EcoRI, XhoI digested construct (in pPA1 LexA) with EcoRI + XhoI digested pJG4-5 (see 
Figure 3.7).
29
 
 
Figure 3.7.  Plasmid map of pJG4-5 SA, used to create new B42- streptavidin fusions (SAnb, dSADD). 
 
Yeast Three Hybrid Assays with Flow-Cytometry:  Frozen competent yeast FY250 were first 
transformed with reporter plasmid pSHyEGFPpst and plated on selective solid media (SD-ura + 2% 
glucose). Multiple large colonies were pooled and inoculated into appropriate liquid selection media and 
grown to saturation (3 mL). Saturated culture was diluted 1:6 in liquid selection media (10 mL), grown to 
mid-log phase (app. 4 h), and resuspended in 200 µL sterile water. An aliquot of yeast concentrate (100 
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µL) was then transformed with the specified bait and prey streptavidin constructs (on vectors pPA1 LexA 
and pJG 4-5, respectively) using the “Quick and Easy” LiAc/SS carrier DNA/PEG method
30
 and plated 
on yeast solid selective media (SD-His-Trp + 2% glucose). From this plate multiple large colonies were 
pooled and grown to saturation in appropriate liquid selection media. Aliquots (100 µL) were pelleted and 
washed once with PBS, then diluted 1:4 in selective 1% raffinose, 2% galactose induction media. 
Cultures were then grown for 8 hours. For biotin treated assays, cultures were induced for 4 h before D-
biotin (1 µM) treatment. Resultant reporter gene fluorescence intensity was measured by flow-cytometry 
(described previously). 
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APPENDIX A. Plasmid List 
Section 1. Empty Plasmids 
Name Source 
Expressed 
Gene 
Restriction Sites Plasmid Type 
Bacterial 
Resistance 
Yeast 
Marker 
Seq. 
Primers 
pBP7-7 BRPeterson 6x His tag 
T7pr-XbaI-
MRGSHHHHHHP-
BamHI-NcoI-KpnI-
MfeI-EcoRI-STOP-
XhoI-SalI-STOP-
HindIII 
Bacterial 
Expression 
Vector, 2µ Ori 
Amp N/A 
5' pLM, 3' 
pLM 
pJG4-5 Brent Lab 
SV40NLS- 
B42 AD-HA 
Gal1pr- HindIII-
SV40 NLS-B42 
AD-HA Tag-
EcoRI-Stuffer-
XhoI-HindIII-
ADH1t 
Yeast Expression 
Vector, YEp 
Amp Trp 1 
5' pJG4-5, 
3' ADH1 
pPA1 
LexA stop 
S 
Athavankar 
HA-
SV40NLS-
LexA 
KpnI-Gal1pr-EcoRI 
KO-HA SV40 
NLS-LexA -EcoRI-
XhoI-stop-ADH1t-
BamHI-SalI-PstI 
Yeast Expression 
Vector, YEp 
Amp LEU2 
5' Gal1, 3' 
ADHI 
 
Section 2. Reporter Constructs 
Name Source 
Expressed 
Gene 
Restriction Sites Plasmid Type 
Bacterial 
Resistance 
Yeast 
Marker 
Seq. 
Primers 
pDCLr 
yEGFP 
D. Clark yEGFP 
KpnI-8x LexAop-
Gal1-10pr region-
EcoRI-yEGFP-
XhoI-ADH1t-
BamHI 
Yeast reporter 
plasmid (LexA 
DBD),YEp 
Amp LEU2 
5' Gal1, 3' 
ADH1 
pDCUd 
yEGFP 
K. Bailey yEGFP 
KpnI-8x LexAop-
Gal1-10pr region-
EcoRI-yEGFP-
XhoI-ADH1t-
BamHI 
Yeast reporter 
plasmid (LexA 
DBD), YEp 
Amp URA3-d 
5' Gal1, 3' 
ADH1 
pSH18-34 Brent Lab 
beta-Gal 
reporter 
N/A 
Yeast reporter 
plasmid (LexA 
DBD),YEp 
Amp Ura 3 
5' Gal1, 3' 
ADH1 
pSH 
yEGFP 
K. Bailey yEGFP 
BamHI-
8xLexAop-Gal1-
10pr region-
yEGFP-XhoI-
ADH1t-SphI 
Yeast reporter 
plasmid (LexA 
DBD),YEp 
Amp URA3 
5' Gal1, 3' 
ADH1 
pSH 
yEGFPpst 
K. Bailey 
yEGFP-
Cln2PEST 
BamHI-
8xLexAop-Gal1-
10pr region-
yEGFP-
Cln2PEST-SalI-
ADH1t-SphI 
Yeast reporter 
plasmid (LexA 
DBD),YEp 
Amp URA3 
5' Gal1, 3' 
ADH1 
pSHIP 
yEGFPpst 
K. Bailey 
yEGFP-
Cln2PEST 
BamHI-
8xLexAop-Gal1-
10pr region-
yEGFP-
Cln2PEST-SalI-
ADH1t-SphI 
Yeast reporter 
plasmid (LexA 
DBD),YIp 
Amp URA3 
5' Gal1, 3' 
ADH1 
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Section 3. Hormone Receptor Constructs 
Name Source 
Expressed 
Gene 
Restriction Sites Plasmid Type 
Bacterial 
Resistance 
Yeast 
Marker 
Seq. 
Primers 
pAM423 
LexA AR 
(670-919) 
S Muddana 
HA-
SV40NLS-
LexA-AR 
(670-919)  
Gal1pr-HA-NLS-
LexA-EcoRI-AR 
(670-919)-SalI-
Stop-XhoI-ADH1t 
Yeast Expression 
Vector, YEp 
Amp His 3 
5' Gal1, 3' 
ADH1 
pAM423 
LexA 
hERβ 
(255-509) 
S. Hussey 
HA-
SV40NLS-
LexA-hERβ 
(255-509) 
KpnI-Gal1pr- HA 
Tag- SV40 NLS- 
LexA-EcoRI-hER 
(305-595)-ADH1t-
BamHI-XbaI-NotI-
SphI-PstI 
Yeast Expression 
Vector, YEp 
Amp His 3 
5' Gal1, 3' 
ADH1 
pAM423 
LexA PR 
(682-933) 
S. Muddana 
HA-
SV40NLS-
LexA-PR 
(682-933) 
KpnI-Gal1pr- HA 
Tag- SV40 NLS- 
LexA-EcoRI PR 
(682-933)-ADH1t-
BamHI-XbaI-NotI-
SphI-PstI 
Yeast Expression 
Vector, YEp 
Amp His 3 
5' Gal1, 3' 
ADH1 
pJG4-5 
AR (670-
919) 
S Muddana 
SV40 NLS-
B42 AD-HA- 
AR (670-
919) 
SacI-KpnI-Gal1pr- 
HindIII-
SV40NLS-B42 
AD-HA-EcoRI-
AR (670-919)- 
XhoI-ADH1t-
SphI-BamHI-SalI 
Yeast Expression 
Vector, YEp 
Amp Trp1 
5' pJG45, 
3' ADHI 
pJG4-5 
hERβ 
(255-509) 
S Muddana 
SV40 NLS-
B42 AD-HA- 
ERβ (255-
509) 
SacI-KpnI-Gal1pr- 
HindIII-
SV40NLS-B42 
AD-HA-EcoRI-
hER (305-595)-
ADH1t-SphI-
BamHI-SalI 
Yeast Expression 
Vector, YEp 
Amp Trp1 
5' pJG45, 
3' ADHI 
pJG4-5 
PR(682-
933) 
S. Muddana 
SV40 NLS-
B42 AD-HA 
-PR (682-
933) 
SacI-KpnI-Gal1pr- 
HindIII-
SV40NLS-B42 
AD-HA-EcoRI-PR 
(682-933)-SalI-
ADH1t-SphI-
BamHI-SalI 
Yeast Expression 
Vector, YEp 
Amp Trp1 
5' pJG45, 
3' ADHI 
 
Section 4. Streptavidin Constructs 
Name Source Expressed Gene Restriction Sites 
Plasmid 
Type 
Bacterial 
Resistance 
Yeast 
Marker 
Seq. 
Primers 
pJG4-5 
dSAAA 
K. 
Bailey 
SV40 NLS-B42 AD-
HA -cpSA87-cpSA54 
Gal1pr- HindIII-SV40 
NLS-B42 AD-HA Tag-
EcoRI-cpSA87-BspEI-
cpSA54-XhoI-HindIII-
ADH1t 
Yeast 
Expression 
Vector, 
YEp 
Amp Trp 1 
5' pJG4-
5, 3' 
ADH1t 
pJG4-5 
cpSAnb54 
K. 
Bailey 
SV40NLS-B42 AD- 
HA Tag-cpSAnb54 
Gal1pr- HindIII-SV40 
NLS-B42 AD-HA Tag-
EcoRI-cpSAnb54-XhoI-
HindIII-ADH1t 
Yeast 
Expression 
Vector, 
YEp 
Amp Trp 1 
5' pJG4-
5, 3' 
ADH1t 
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pPA1 
LexA 
cpSA54 
K. 
Bailey 
HA-SV40NLS-LexA-
cpSA54 
KpnI-Gal1pr-EcoRI 
KO-HA SV40 NLS-
LexA -EcoRI-BspEI-
cpSA54-XhoI-ADH1t-
SalI-PstI 
Yeast 
Expression 
Vector, 
YEp 
Amp LEU2 
5' Gal1, 
3' 
ADH1t 
pPA1 
LexA 
cpSA87 
K. 
Bailey 
HA-SV40NLS-LexA-
cpSA87 
KpnI-Gal1pr-EcoRI 
KO-HA SV40 NLS-
LexA -EcoRI-cpSA87-
BspEI-stop-XhoI-
ADH1t-SalI-PstI 
Yeast 
Expression 
Vector, 
YEp 
Amp LEU2 
5' Gal1, 
3' 
ADH1t 
pPA1 
LexA 
cpSAnb54 
K. 
Bailey 
HA-SV40NLS-LexA-
cpSAnb54 
KpnI-Gal1pr-EcoRI 
KO-HA SV40 NLS-
LexA -EcoRI-BspEI-
cpSAnb54-XhoI-
ADH1t-SalI 
Yeast 
Expression 
Vector, 
YEp 
Amp LEU2 
5' Gal1, 
3' 
ADH1t 
pPA1 
LexA 
cpSAnb87 
K. 
Bailey 
HA-SV40NLS-LexA-
cpSAnb87 
KpnI-Gal1pr-EcoRI 
KO-HA SV40 NLS-
LexA -EcoRI-
cpSAnb87-BspEI-stop-
XhoI-ADH1t-SalI 
Yeast 
Expression 
Vector, 
YEp 
Amp LEU2 
5' Gal1, 
3' 
ADH1t 
pPA1 
LexA 
dSAAA 
K. 
Bailey 
HA-SV40NLS-LexA-
cpSA87-cpSA54 
KpnI-Gal1pr-EcoRI 
KO-HA SV40 NLS-
LexA-cpSA87-BspEI-
cpSA54-XhoI-ADH1t-
SalI-PstI 
Yeast 
Expression 
Vector, 
YEp 
Amp LEU2 
5' Gal1, 
3' 
ADH1t 
pPA1 
LexA 
dSAAD 
K. 
Bailey 
HA-SV40NLS-LexA-
cpSA87-cpSAnb54 
KpnI-Gal1pr-EcoRI 
KO-HA SV40 NLS-
LexA-cpSAnb87-
BspEI-cpSAnb54-XhoI-
ADH1t-SalI 
Yeast 
Expression 
Vector, 
YEp 
Amp LEU2 
5' Gal1, 
3' 
ADH1t 
pPA1 
LexA 
dSADD 
K. 
Bailey 
HA-SV40NLS-LexA-
cpSAnb87-cpSAnb54 
KpnI-Gal1pr-EcoRI 
KO-HA SV40 NLS-
LexA-cpSAnb87-
BspEI-cpSAnb54-XhoI-
ADH1t-BamHI-SalI 
Yeast 
Expression 
Vector, 
YEp 
Amp LEU2 
5' Gal1, 
3' 
ADH1t 
pPA1 
LexA SA 
K. 
Bailey 
HA-SV40NLS-LexA--
SA 
KpnI-Gal1pr-EcoRI 
KO-HA SV40 NLS-
LexA -SA-EcoRI-XhoI-
stop-ADH1t-BamHI-
SalI-PstI 
Yeast 
Expression 
Vector, 
YEp 
Amp LEU2 
5' Gal1, 
3' 
ADH1t 
pPA1 
LexA 
SAnb 
K. 
Bailey 
HA-SV40NLS-LexA-
SA(N23A,S27D,S45A) 
KpnI-Gal1pr-EcoRI 
KO-HA SV40 NLS-
LexA -
SA(N23A,S27D,S45A)-
EcoRI-XhoI-stop-
ADH1t-BamHI-SalI-
PstI 
Yeast 
Expression 
Vector, 
YEp 
Amp LEU2 
5' Gal1, 
3' 
ADH1t 
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pSA1 
T7SAwt 
B42 
S 
Hussey 
T7SAwt-NLS-B42 
AD-HA tag-stop 
KpnI-Gal1pr-T7 SAwt-
NLS-B42-HA tag-
EcoRI-XhoI-stop-
ADH1t 
Yeast 
Expression 
Vector, 
YEp 
Amp TRP1 
5' Gal1, 
3' 
ADH1t 
 
 
APPENDIX B. Protein Sequences 
 
yEGFP: Yeast enhanced variant of EGFP used as fluorescent reporter gene 
Cormack, B. P. e. Microbiology 1997, 143 ( Pt 2), 303. 
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SV40NLS-B42-HA: Used for B42 AD fusion proteins 
Gyuris, J. et al. H.; Brent, R. Cell 1993, 75, 791. 
 
 
 
 
HA-SV40NLS-LexA: Used for LexA DBD fusion proteins 
Gyuris, J. et al. H.; Brent, R. Cell 1993, 75, 791. 
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Cln(PEST): Protein destabilization tag used to reduce yEGFP half-life. 
Salama, S. R.; Hendricks, K. B.; Thorner, J. Mol Cell Biol 1994, 14, 7953. 
 
 
 
SA(13-139): Core streptavidin(13-139) used as template and benchmark for all SA variants. 
Sano, T. et al. J Biol Chem 1995, 270, 28204. 
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pSHyEGFPpst: Full sequence of improved plasmid used for streptavidin three-hybrid assays. 
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SAnb: Core streptavidin with negligible biotin affinity due to N23A, S27D, S45A mutations (underlined). 
Silent PstI restriction site (blue) added for screening. 
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cpSA87: Circular permutation of core streptavidin beginning with E116 (between 7
th
 and 8
th
 β-strands). 
BamHI restriction site (blue) embedded in GGGS linker (blue) for screening. Mutations N23A (gct), 
D27A (gat), and S45A are made for cpSAnb87 (underlined, silent PstI made but not shown). C-terminal 
SG added with embedded BspEI (blue) for dSA cloning. 
 
 
cpSA54: Circular permutation of core streptavidin beginning with S69 (between 4
th
 and 5
th
 β-strands). 
BamHI restriction site (blue) embedded in GGGS linker (blue) for screening. Mutations N23A (gct), 
D27A (gat), and S45A are made for cpSAnb54 (underlined, silent PstI made but not shown). N-terminal 
SG codons mutated to embed silent BspEI (blue) for dSA cloning. 
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ERβ(255-509):  Human estrogen receptor beta ligand binding domain (255-509) used in ERβ 
homodimerization yeast three-hybrid assays.   
Ogawa, S. et al. M. Biochem Biophys Res Commun 1998, 243, 122.
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PR(682-933): Human progesterone receptor ligand binding domain (682-933) used in PR 
homodimerization yeast three-hybrid assays.  The unintended P906S mutation is shown in blue. 
Misrahi, M et al. Biochem Biophys Res Commun 1987, 143, 740. 
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AR(670-919): Human androgen receptor ligand binding domain (670-919) used in AR homodimerization 
yeast three-hybrid assays. 
Laitinen, O. H. et al. Trends Biotechnol 2007, 25, 269. 
 
 
 
 
 
APPENDIX C. Microbial Stains 
 
Name Cell Type Source Genotype Comments 
DH5α E. coli Invitrogen 
F- F50dlacZDM15 D(lacZYA-
argF) U169 recA1 endA1 
hsdR17(rk-mk+) pho|A supE44 l- 
thi-1 gyrA96 relA1 
General 
subcloning 
FY250 S. cerevisiae M. Ptashne 
MATα, ura3-52, hisD200, 
leu2D1, trp1D63 
General 
yeast strain 
FY250yEGFPpst S. cerevisiae K. Bailey 
MATα, ura3-52, 
URA3::yEGFPpst, hisD200, 
leu2D1, trp1D63 
yEGFPpst 
integrated 
reporter 
strain 
 
